Skip to main content

What the FDA labels say about taking them together

Amiodarone and rimegepant

Rimegepant's FDA label of June 4, 2026 names amiodarone in its drug interactions section; the amiodarone labels PlainMeds reads (2) do not name rimegepant. The rimegepant label: “Concomitant administration of NURTEC ODT with potent inhibitors of P-gp may result in increased exposure of rimegepant.”

Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the rimegepant FDA label on DailyMed (effective June 4, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the amiodarone label say about rimegepant?

Amiodarone's label (effective December 9, 2025) and its 1 other brand-application label do not name rimegepant in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed

What does the rimegepant label say about amiodarone?

Rimegepant label, drug interactions

Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant.

Source: FDA drug label (NURTEC ODT), Pfizer Laboratories Div Pfizer Inc, effective June 4, 2026 (SPL set 9ef08e09-1098-35cc-e053-2a95a90a3e1d), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

32Amiodarone generic labelers
0Rimegepant generic labelers
AmiodaroneRimegepant
Labeled forn/aMigraine
Boxed warningYesNo
Pharmacy cost (NADAC)$0.122 per tablet 200 mg tablet$128.67 per tablet 75 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?